Which prophylaxis guidelines are correct for opportunistic infections based on CD4 counts?

Which prophylaxis guidelines are correct for opportunistic infections based on CD4 counts?

• A. No prophylaxis is recommended.
• B. PJP prophylaxis only when CD4 < 200.
• C. PJP prophylaxis with TMP-SMX when CD4 < 100; toxoplasma prophylaxis with TMP-SMX when CD4 < 100; MAC prophylaxis with azithro/clarithro when CD4 < 50.
• D. Prophylaxis for MAC when CD4 < 100.

Answer: (C)

Prophylaxis for opportunistic infections is guided by how suppressed the immune system is, judged by the CD4 count, and it targets the infections most likely to occur at each level. TMP-SMX is the go-to drug because it protects against both Pneumocystis jirovecii pneumonia and toxoplasma gondii. When the immune system is sufficiently weakened (the lower CD4 range), you use TMP-SMX to prevent these two infections. As the immune suppression becomes deeper, the risk for Mycobacterium avium complex increases, and prophylaxis with a macrolide such as azithromycin or clarithromycin is added. The option aligns with this approach by recommending TMP-SMX to prevent Pneumocystis and toxoplasmosis at the same threshold, and adding azithromycin or clarithromycin to prevent MAC at the deeper level of immunosuppression. This combination covers the major opportunistic infections at their respective risk levels, which is why it is the best match among the choices. The other options are incomplete: removing prophylaxis entirely isn’t appropriate for someone with significant immune suppression, and noting MAC alone without addressing Pneumocystis and toxoplasma leaves out common, preventable risks.

Prophylaxis for opportunistic infections is guided by how suppressed the immune system is, judged by the CD4 count, and it targets the infections most likely to occur at each level. TMP-SMX is the go-to drug because it protects against both Pneumocystis jirovecii pneumonia and toxoplasma gondii. When the immune system is sufficiently weakened (the lower CD4 range), you use TMP-SMX to prevent these two infections. As the immune suppression becomes deeper, the risk for Mycobacterium avium complex increases, and prophylaxis with a macrolide such as azithromycin or clarithromycin is added.

The option aligns with this approach by recommending TMP-SMX to prevent Pneumocystis and toxoplasmosis at the same threshold, and adding azithromycin or clarithromycin to prevent MAC at the deeper level of immunosuppression. This combination covers the major opportunistic infections at their respective risk levels, which is why it is the best match among the choices.

The other options are incomplete: removing prophylaxis entirely isn’t appropriate for someone with significant immune suppression, and noting MAC alone without addressing Pneumocystis and toxoplasma leaves out common, preventable risks.